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Abstract
Background: Prostate-specific antigen (PSA) test is of par-
amount importance as a diagnostic tool for the detection 
and monitoring of patients with prostate cancer. In the 
presence of interfering factors such as heterophilic anti-
bodies or anti-PSA antibodies the PSA test can yield sig-
nificantly falsified results. The prevalence of these factors 
is unknown.
Methods: We determined the recovery of PSA concentra-
tions diluting patient samples with a standard serum of 
known PSA concentration. Based on the frequency dis-
tribution of recoveries in a pre-study on 268  samples, 
samples with recoveries <80% or >120% were defined as 
suspect, re-tested and further characterized to identify the 
cause of interference.
Results: A total of 1158 consecutive serum samples were 
analyzed. Four samples (0.3%) showed reproducibly dis-
turbed recoveries of 10%, 68%, 166% and 4441%. In three 
samples heterophilic antibodies were identified as the 
probable cause, in the fourth anti-PSA-autoantibodies. 
The very low recovery caused by the latter interference was 
confirmed in serum, as well as heparin- and EDTA plasma 
of blood samples obtained 6  months later. Analysis by 
eight different immunoassays showed recoveries ranging 
between <10% and 80%. In a follow-up study of 212 
random plasma samples we found seven samples with 
autoantibodies against PSA which however did not show 
any disturbed PSA recovery.
Conclusions: About 0.3% of PSA determinations by the 
electrochemiluminescence assay (ECLIA) of Roche diag-
nostics are disturbed by heterophilic or anti-PSA autoan-
tibodies. Although they are rare, these interferences can 
cause relevant misinterpretations of a PSA test result.
Keywords: autoantibodies; heterophilic antibodies; 
immunoassay; prostate-specific antigen (PSA); prostate; 
recovery.
Introduction
Prostate-specific antigen (PSA) is a very important bio-
marker for the detection, staging and monitoring of 
patients with prostate cancer [1, 2]. Elevated PSA levels 
may lead to diagnostic interventions (i.e. prostate biopsy 
[3]) or in some cases even trigger additional therapies (i.e. 
androgen deprivation or salvage radiation) for patients 
with known prostate cancer [4, 5]. Hence, a PSA immuno-
assay must provide accurate and reproducible results as 
they directly influence important clinical decisions.
Immunoasssays using monoclonal antibodies are 
generally robust but may be disturbed by interferences 
such as heterophilic antibodies (hAs) or auto antibodies 
[6, 7]. Several incidents of falsely elevated PSA levels as 
the result of hAs have been reported [8–10] and in some 
cases this led to severe overtreatment of patients [11, 
12]. Due to the fact that these interferences are widely 
unknown in the urologic community, it can be assumed 
that there is a relevant number of unknown cases. Also 
auto antibodies against PSA have been described to occur 
in men with prostate cancer, benign prostate hypertrophy 
or immunoinfertility at prevalences ranging between 3% 
and 30% [13, 14]. At least in theory PSA-autoantibodies 
can result in false-low levels of PSA and subsequently 
underdiagnosis and undertreatment of incident or relaps-
ing prostate cancer. As yet the prevalence of these inter-
ferences has not been systematically investigated [15, 16]. 
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This is in contrast to the monitoring of thyroid cancer by 
thyroglobulin (TG) [17], after thyroidectomy and radiation 
[18]. International guidelines mandate that every TG test 
must be accompanied by the measurement of anti-TG anti-
bodies and/or the recovery of TG added to the sample [19].
In this study we investigated the prevalence and 
underlying reasons for disturbed PSA measurements in a 
large consecutive series of serum samples.
Materials and methods
Study design
From February to May 2014 all sera which were sent to the Insti-
tute for Clinical Chemistry for a PSA measurement were routinely 
analyzed for recovery. As the first step, a pilot study was performed 
on 268 samples to determine the frequency distribution of recover-
ies. The 99.7% confidence interval was defined as the normal range 
and ranged from 80% to 120%. As the second step 1158 consecutive 
samples were screened to identify samples with recoveries of less 
than 80% or more than 120%. Pathological samples were re-analyzed 
for recovery and by scantibodies to identify samples with reproduc-
ibly abnormal recovery and hA, respectively. Finally we approached 
patients with reproducibly abnormal recovery to obtain novel blood 
samples. Figure 1 shows the flowchart of the conducted study.
Both the screening study and the patient characterization were 
approved by the Local Ethics Committee.
Quantification of PSA concentrations and PSA recoveries
PSA was determined by a 3rd generation electrochemilumines-
cence assay (ECLIA) from Roche diagnostics using the e601 unit of 
Figure 1: Study flow chart of the conducted study.
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a COBAS8000 system (Rotkreuz, Switzerland). To determine recov-
eries, we mixed 190 μL of original patient samples with 10 μL of a 
sample from a patient with a very high PSA level (Pool) level of 128 ± 5 
μg/L. Recovery was defined as the ratio of observed PSA concentra-
tions to expected PSA concentrations in the mixed samples (observed 
PSA/expected PSA in %). The expected PSA concentration was cal-
culated the following: μg/L PSA in pool serum*10 μL + μg/L PSA in 
patient serum*190 μL)/200 μL.
As the result of the pilot study, recoveries of <80% or >120% 
were defined as abnormal.
PSA recovery of one specific sample was also analysed by using 
eight different PSA immunoassays in collaborating laboratories (see 
acknowledgements).
Heterophilic antibodies
Sera with disturbed recovery were incubated with a blocking reagent 
for hAs (Scantibodies Heterophilic Blocking Reagent; Scantibodies 
Laboratory Inc., Santee, CA, USA) before PSA was determined. In 39 
randomly selected sera (14 frozen, 25 fresh) we assessed the concen-
trations of PSA before and after incubation with the blocking reagent 
and thereby found recoveries of 96% + 9.5%. We therefore defined a 
range of 67%–124% (μ ± 3σ) as non-pathologic absorbance.
Anti-PSA autoantibodies
Anti-PSA autoantibodies were detected by indirect ELISA against 
purified PSA-antichymotrypsin (ACT) complex (provided by Roche 
diagnostics, Penzberg, Germany), ACT, and free PSA (Sigma).
Briefly, PSA-ACT, free PSA or ACT in 100 mM carbonate-bicar-
bonate buffer pH 9.6 were bound to polystyrene microtiter plates 
overnight at 4 °C, followed by extensive washing. The wells were 
then incubated with blocking buffer (2% BSA in PBS 0.1% Tween20) 
for 2 h at room temperature. After a second washing step, plasma 
samples diluted in blocking buffer were then added to each well. 
The plate was incubated under these conditions at 4 °C overnight 
on a plate shaker. A third washing step was then performed before 
an HRP-conjugated antibody against human IgG (Jackson Immun-
Research) diluted in blocking buffer was added for 2 h at room tem-
perature. After a further washing step, HRP activity was detected 
by using an ABTS substrate solution (Roche). Absorbance was 
read at 405  nm with an automated plate reader (Tecan, Biotek). 
The absorbance at 490  nm was used as a reference. All washing 
steps were carried out using an EL406 washer-dispenser (Biotek). 
The washing buffer employed was PBS 0.1% Tween20. The plasma 
samples and the anti-IgG antibody were diluted as reported in the 
figure legends.
Detection was performed using an HRP-conjugated polyclonal 
rabbit anti-mouse secondary antibody (Dako). The anti-PSA-anti-
body search test was developed only for this research study and is 
not part of our clinical routine diagnostics.
Anti-PSA-ACT autoantibodies in plasma were also detected by 
western blotting. Briefly, 1 μg of pure PSA-ACT was separated on a 
10% SDS-PAGE gel in reducing conditions followed by transfer to a 
nitrocellulose membrane. Detection was performed using the Pierce 
ECL Plus western blot substrate (Thermo Scientific) on a Fusion FX 
chemiluminescence imaging station (Viber Luormat).
For further detection of anti-PSA autoantibodies, immunohis-
tochemistry on prostate cancer cells was performed. The human 
prostate cancer cell-line PC3 [20] were obtained from the American 
Type Culture Collection (Manassas, VA, USA) and cultured as pre-
viously described [21]. Cells were stained using the serum of the 
patient as a primary antibody and anti-human IgG as a secondary 
antibody. Immunohistochemistry was carried out on a Leica Bond 
immunostainer (Leica Microsystems, Newcastle, UK) according to 
the manufacturer’s instructions.
Results
Discovery studies
The pilot study on 268 samples revealed a mean recovery 
of 104% with a standard deviation (SD) of 7% and a ±3 SD 
ranging from 83% to 125%. We therefore defined recover-
ies of less than 80% or more than 120% as pathological. 
A prevalence of 5% off all samples showed initial recov-
eries outside of this range (Figure 1). Re-testing of these 
suspect samples confirmed pathological recoveries in four 
samples: 10% (Patient 1), 68% (Patient 2), 165% (Patient 
3), and 4441% (Patient 4). (Table 1 and Supplemental 
Figure 1). Thus, four out of 1158  samples showed repro-
ducibly pathological recoveries (prevalence of 0.3%).
To identify the reason for the interferences we first 
checked the samples for the presence of hA by using the 
adsorber test from Scantibodies. Three samples showed 
strongly pathological recoveries of 826,300% (Patient 
4), 3123% (Patient 3), and 2% (Patient 2). The sample of 
Patient 1  showed a borderline pathological recovery of 
63% (Table 1).
Case reports and validation studies
The four patients with reproducibly abnormal recovery 
were invited to provide novel blood samples to test for 
persistence of the interference, the impact of the sample 
matrix and the presence of anti-PSA autoantibodies 
(Figure 1). In addition, an extended clinical history was 
recorded to identify exposures that may explain the pres-
ence of hA (Table 2). As Patient 4 had died in the mean-
time, only three of the four patients could be contacted.
The PSA of Patient 1 was requested as part of a routine 
check up. He had a history of prostatoepididymitis and 
had received one blood transfusion. Patient 2  suffered 
from lower urinary tract syndrome (LUTS), but also had 
pure red cell aplasia. For this reason he was exposed to 
many blood transfusions as well as with one human 
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immunoglobuline infusion (KIOVIG™). Patient 3 was suf-
fering from LUTS and had no history of any exposure to 
any transfusion. Patient 4  had suffered from castration 
resistant prostate cancer at the time point of first sample 
testing. He died shortly thereafter as a result of his meta-
static disease. He had a history of blood tranfusion.
PSA concentrations and recoveries were determined 
in the newly obtained blood samples from the three living 
patients (Table 1). Interestingly, recoveries were normal 
in sera of Patients 2 and 3, but severely decreased to less 
than 10% in Patient 1 no matter whether PSA was quanti-
fied in serum, EDTA-plasma or Li-Heparinate-plasma. As 
a further indication of the interference the free PSA con-
centration (2.26 μg/L) was much higher than the appar-
ent total PSA concentration (0.16 μg/L). The recovery of 
PSA was found variably reduced upon quantification by 
different immunoassays from different manufacturers: 
Four assays showed borderline to intermediate recoveries 
of 57%–80%, whereas four other assays showed severely 
reduced recoveries of 5%–16% like the Roche Cobas assay 
(Table 3).
Finally we tested the sample of Patient 1 for the pres-
ence of anti-PSA antibodies by indirect immunostaining 
of PC3 prostate cancer cells, western blotting, and ELISA. 
Immunohistochemistry of PC3 using the serum of Patient 
1 confirmed the presence of anti-PSA antibodies in the 
patient serum. PC3 prostate cancer cells showed a dose 
dependent positive PSA-like immunoreactivity when the 
patient serum was used a primary antibody (Figure 2A–C). 
Western blotting of purified PSA with the patient serum 
but not with control serum identified immuno-reactiv-
ity against the PSA-ACT-antigen used in the total PSA 
assay. The purity, integrity and molecular weight of the 
PSA-ACT complex were confirmed by SDS-PAGE followed 
by Comassie staining (Figure 2D). By ELISA, we found 1:10 
and 1:5 dilutions of the patient plasma as anti-PSA-immu-
noreactive (Figure 3A). Plasma samples from 212 randomly 
selected male patients from the sample archive of the 
institute of clinical chemistry identified seven samples 
with significant immunoreactivity against the PSA-ACT 
antigen (Figure 3B). However, all of them showed normal 
recoveries both of total PSA and free PSA. Therefore we 
analysed the immunoreactivity of the plasma of Patient 1 
as well as the plasmas of the seven patients with immuno-
reactivity against the ACT/PSA complex for their immuno-
reactivity against free PSA, ACT, and the ACT-PSA complex 
purchased from Sigma (Figure 3C). The disturbed sample 
of Patient 1  showed immunoreactivity against both the 
pure and ACT-complexed PSA but none against ACT. The 
immunoreactivity pattern of the other seven samples was 
more heterogenous: Samples A, C, D, E, and G immuno-
reacted with all three antigens whereas samples B and F 
reacted with only free PSA but not with complexed PSA or 
ACT (Figure 3C).
Discussion
To our knowledge this is the first systematic study on 
the prevalence and underlying reasons of disturbed PSA 
recovery in a large consecutive series of clinical serum 
samples. We determined recoveries by patients’ plasmas 
with a small amount of a pool plasma with very high PSA 
concentration. The spiking plasma hence accounted for 
only 5% of the final sample. This very low amount makes 
artificial interferences by the spiking plasma unlikely. 
In line with this the frequency distribution of recoveries 
ranged from 80% to 120% both in the pilot and the vali-
dation. Any interference by the spiking plasma should 
have resulted in a frequency distribution that is skewed to 
values either lower or higher than 100%.
Among 1158  sera we identified four samples (0.3%) 
with reproducibly pathological recoveries. However, the 
interference was found to persist in only one sample over 
time when samples were retested several month later. 
This persistent interference was found to be associated 
with the presence of anti-PSA auto-antibodies whereas 
the non-persistent interference was associated with the 
presence of hA.
The prevalence of hA in serum samples was reported 
to vary from 3% to 40% [16, 22]. However, clinically more 
important is the prevalence of disturbed PSA levels due 
to hA in routine PSA assessment. In line with our results, 
Anderson et al. [15] estimated the prevalence of spuriously 
elevated PSA values in patients after curative treatment 
Table 3: PSA recoveries as determined in the serum of Patient 1.
Roche 
Cobas
Abbott 
Architect
Siemens 
Advia Centaur
Beckman 
Hybritech
Beckman 
Access 2
Siemens 
Immulite
i-chroma Biomerieux 
mini Vidas
Siemens 
Dimension Vista 
Measured PSA, ng/mL 0.16 0.15 1.72 2.77 3.4 3.18 0.1 0.29 0.08
Recovery, % 9 16 57 66 80 80 6 15 6
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for prostate cancer in their study to be 0.3%. However, 
the tested population was highly selected (only patients 
after curative treatment for prostate cancer) and cannot 
be directly compared with ours. Our study was performed 
on unselected samples of male patients, who underwent 
PSA testing for different reasons, i.e. screening or uro-
logical work-up for suspected prostate cancer, monitoring 
of treatment for prostate cancer. Moreover, our reported 
prevalence is not estimated but determined.
HA are human immunoglobulins that bind against 
different animal antigens, for example from mice. Inter-
ference of hA with immunoassays has been known since 
the 1980s [7]. Most PSA assays including ours from Roche 
diagnostics use a solid-phase immunoglobulin G to bind 
the PSA molecule. A second immunoglobulin, marked 
with a tracer, binds subsequently to the PSA molecule for 
measurement. As hAs can bind to either immunoglobu-
lin, the presence of hAs can lead to false-positive or, more 
rarely, false-negative results by cross-binding the assay 
antibodies [7, 23].
Usually, the reason for the presence of a hA in a serum 
remains unkown. Samples of patients formerly exposed 
to animals or animal serum products, immunoglobulin 
therapy or immunoscintigraphy are more likely to contain 
hAs [24]. HAs can also result from infections by rubella, 
measles, adeno-, entero-, and varicella-zoster viruses [25]. 
Our patients show several of these risk factors. Of note, 
the interference with hAs did not persist over time but 
disappeared in samples newly obtained several months 
after the initial sample. Also in the patient of our previous 
case-report [10], we observed disappearance of the inter-
ference during a follow-up of several months (Poyet et al. 
unpublished).
Previously, interference of PSA assays by hA became 
obvious by falsely elevated PSA values during screen-
ing [8, 11, 26], persistence of elevated PSA [10, 12, 27, 28] 
or PSA recurrence after curative treatment [9, 29]. A rel-
evant amount of these reported cases led to unnecces-
sary salvage treatments or diagnostic investigations for 
metastasis.
Anti-PSA autoantibodies were found in one patient 
as the cause of severely decreased PSA recovery. Of note, 
the autoantibodies only interfered with the determina-
tion of total PSA but not free PSA. A finding of free PSA 
Figure 2: Demonstration of the anti-PSA antibody in the patient serum by Immunohistochemistry of formalin-fixed paraffin-embedded PC3 
prostate cancer cells (A–C) and Western Blotting (D).
(A) Negative control (without patient serum, IgG was used as secondary antibody). (B) Serum of the patient was used instead of a primary 
antibody (concentration 1:500). (C) Serum of the patient was used instead of a primary antibody (concentration 1:100). (D) A purified 
PSA-ACT complex was electrophoresed by SDS-PAGE and stained with Comassie blue (*) or transferred to nitrocellulose for immunodetection 
by a mouse monoclonal anti-PSA antibody (**), a serum pool (***) or the serum of Patient 1 (****).
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levels being as high or even higher than total PSA levels 
may hence serve as an indication of interference. Low or 
even undetectable total-PSA with high levels of free-PSA 
due to possible presence of autoantibodies has been 
previously reported [30, 31]. This erroneous phenom-
enon was not present in all tested PSA immunoassays, 
suggesting dependence on the selected PSA-antibodies 
used [30].
In our study, the autoantibody interfered with the 
measurement of PSA by nine investigated immunoassays, 
however to very different degrees with recoveries ranging 
from less than 10% to about 80%. Interestingly, our fol-
low-up study identified the presence of PSA autoantibod-
ies in >3% of patient sera from our hospital. Previously 
reported prevalences of anti-PSA antibodies amounted to 
0% in young healthy males and females, 16% and 40% 
in infertile men and women, respectively, and 33% and 
59% in men with benign prostate hypertrophy [13, 14, 32]. 
Importantly however, none of the autoantibodies identi-
fied in our prevalence study interfered with the determi-
nation of PSA by the Roche Assay, even when their titres 
were higher than that in the sample of Patient 1.
Several different prominent epitopes have been iden-
tified within the PSA molecule. These various epitopes 
may react differently with the antibodies used by the dif-
ferent PSA assays [33]. Van Duijnhoven et  al. reported a 
case report on large discrepancies between PSA levels 
measured by different assays, possibly due to the pres-
ence of PSA autoantibodies. They discussed possible 
reasons and concluded that the PSA molecule of this spe-
cific patient may have an alternative structure, leading to 
a diminished recognition by the anti-PSA antibodies used 
in the affected assays, and may have a reduced binding of 
ACT [34].
Obviously only auto-antibodies with a specific epitope 
possibly shared with the antibodies of the PSA immunoas-
say interfere with the PSA immunoassay.
Likewise only a minority of anti-TG antibodies 
interferes with the measurement of TG so that several 
guidelines on the monitoring of thyroid cancer patients 
recommend the determination of TG recovery instead of or 
in addition to the determination of anti-TG antibodies [19].
Unrecognized interference of hA or anti-PSA autoan-
tibodies with the PSA assay can lead to severe clinical 
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Figure 3: Detection of autoantibodies against PSA, PSA-ACT and ACT.
(A) Indirect ELISA against PSA-ACT. Comparison between Subject 1 and a control plasma pool. Data points represent the mean corrected 
absorbance (±SD) of quadruplicate measurements. The reciprocal of the dilution factor used to dilute the plasma samples is reported on 
the x-axis. (B) Indirect ELISA against PSA-ACT. Plasma samples from 212 randomly selected samples were tested together with plasma from 
subject 1 to determine the frequency of autoantibodies. Data points represent the mean corrected absorbance of duplicate measurements 
expressed as a percentage of the mean absorbance for subject 1. Samples that displayed a reactivity beyond the 99% CI of the population 
are highlighted in red. S1: subject 1. (C) Indirect ELISA against PSA, PSA-ACT and ACT. Samples A to G are the samples highlighted in red in 
panel B. S1: subject 1. CT pool: control pool.
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consequences. Given the wide clinical use of PSA assays 
in many countries and medical disciplines, a preva-
lence of interfering hA or anti-PSA antibodies amount-
ing to 4 in 1158 puts a relevant number of men at risk 
of under- or over-diagnosis. As an important limitation, 
our study does not allow any conclusion whether preva-
lences of interfering hA’s and anti-PSA autoantibodies 
vary among different patient groups and/or PSA assays. 
It may well be that the prevalence of these interferences 
with PSA measurement is affected by the specific immu-
noassay used or the presence or therapy of prostate 
cancer, or by other diseases. Nevertheless, our study 
adds important information about the prevalance of 
PSA disturbance in a large unselected male population. 
It raises the question of whether PSA measurements like 
TG measurements should be controlled by the determi-
nation of recovery.
Conclusions
We conclude that the prevalence of PSA measurements 
interfered by hA’s or anti-PSA-autoantibodies is about 
0.3%. Because of the high incidence of PSA testing, this 
rate puts a significant number of men at risk for a misin-
terpretation of their PSA test results.
In case of implausibly high or low PSA levels, the test 
should be repeated with a different PSA assay. Further 
work-up should also include the determination of PSA 
recovery. If the recovery is pathological, hA’s and anti-PSA 
antibodies are prime candidates for underlying causes.
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